As European markets experience an upswing, with the pan-European STOXX Europe 600 Index rising by 3% amid hopes for geopolitical de-escalation, investors are keenly observing companies that exhibit both growth potential and significant insider ownership. In this context, a strong insider presence can signal confidence in a company’s future prospects and alignment of interests between management and shareholders, making such stocks particularly appealing in today’s market environment.
Top 10 Growth Companies With High Insider Ownership In Europe
|
Name |
Insider Ownership |
Earnings Growth |
|
XTPL (WSE:XTP) |
23.3% |
83% |
|
KebNi (OM:KEBNI B) |
11.8% |
82.7% |
|
Hacksaw (OM:HACK) |
13.2% |
24.8% |
|
Envipco Holding (ENXTAM:ENVI) |
19.5% |
91.1% |
|
CTT Systems (OM:CTT) |
17.4% |
47.1% |
|
Clavister Holding AB (publ.) (OM:CLAV) |
18% |
83.1% |
|
Circus (XTRA:CA1) |
21.9% |
84.3% |
|
Bonesupport Holding (OM:BONEX) |
10.6% |
33.8% |
|
BioArctic (OM:BIOA B) |
32.2% |
53.3% |
|
Bergen Carbon Solutions (OB:BCS) |
11.9% |
50.2% |
Here’s a peek at a few of the choices from the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: DNO ASA is involved in the exploration, development, and production of oil and gas assets across the Middle East, the North Sea, and West Africa, with a market cap of NOK18.75 billion.
Operations: The company’s revenue from oil and gas activities amounts to $1.91 billion.
Insider Ownership: 13.1%
DNO is positioned for growth with forecasts indicating it will become profitable in the next three years, outperforming average market growth. Despite high debt levels and a dividend not fully covered by earnings, DNO’s insider ownership is significant with more shares bought than sold recently. The company trades at a substantial discount to its estimated fair value and has shown strong sales growth, reporting US$627.3 million in Q1 2026 compared to US$187.6 million the previous year.
Simply Wall St Growth Rating: ★★★★★★
Overview: BioArctic AB (publ) is a Swedish company focused on developing biological drugs for central nervous system disorders, with a market cap of SEK29.26 billion.
Operations: BioArctic AB (publ) generates revenue primarily from the development of biological drugs targeting central nervous system disorders in Sweden.
Insider Ownership: 32.2%
BioArctic is poised for substantial growth, with forecasted revenue and earnings expected to outpace the Swedish market significantly. Despite a recent decline in sales to SEK 437.59 million and net income to SEK 212.39 million in Q1 2026, insider ownership remains robust without significant trading activity over the past three months. The company’s strategic collaboration on Alzheimer’s treatments highlights its innovative potential, though profit margins have tightened from last year’s levels.
